

ASTRAZENECA PLC  
Form 6-K  
March 28, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of March 2017

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

28 March 2017 16:00 BST

## TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 28 March 2017, awards of the Company's ordinary shares of \$0.25 each (Ordinary Shares) and of American Depositary Shares (ADSs) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP). Two ADSs are equivalent to one Ordinary Share.

The AZDBP award was granted on 28 March 2014, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2013 performance into Ordinary Shares or ADSs, and vested on completion of the three-year holding period.

The AZPSP award was granted on 28 March 2014. Following the application of performance measures specified at the time of grant, 92% of the AZPSP vested and the remaining unvested part immediately and irrevocably lapsed.

Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares and ADSs changed as detailed in the table below:

| PDMR          | Ordinary Shares acquired under the AZDBP | ADSs acquired under the AZDBP | Ordinary Shares acquired under the AZPSP | ADSs acquired under the AZPSP |
|---------------|--|-------------------------------|--|-------------------------------|
| Pascal Soriot | 14,209                                   |                               | 101,584                                  |                               |
| Marc Dunoyer  | 1,419                                    |                               | 25,478                                   |                               |
| Mark Mallon   |  | 620                           |  | 22,000                        |

For tax purposes, the fair market value of an Ordinary Share at vest was 4974.5 pence and the fair market value of an ADS at vest was \$31.80, being the relevant closing prices on the last trading day preceding the vesting day.

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

### About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

Media Enquiries

|                  |           |                  |
|------------------|-----------|------------------|
| Esra Erkal-Paler | UK/Global | +44 203 749 5638 |
| Vanessa Rhodes   | UK/Global | +44 203 749 5736 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding     | UK/Global | +44 203 749 5821 |
| Jacob Lund       | Sweden    | +46 8 553 260 20 |
| Michele Meixell  | US        | +1 302 885 2677  |

Investor Relations

|                     |  |                  |
|---------------------|--|------------------|
| Thomas Kudsk Larsen |  | +44 203 749 5712 |
| Craig Marks         | Finance, Fixed Income, M&A             | +44 7881 615 764 |
| Henry Wheeler       | Oncology                               | +44 203 749 5797 |
| Mitchell Chan       | Oncology                               | +1 240 477 3771  |
| Lindsey Trickett    | Cardiovascular & Metabolic Diseases    | +1 240 543 7970  |
| Nick Stone          | Respiratory                            | +44 203 749 5716 |
| Christer Gruvris    | Autoimmunity, Neuroscience & Infection | +44 203 749 5711 |
| US toll free        |  | +1 866 381 7277  |

Adrian Kemp  
Company Secretary, AstraZeneca PLC

<sup>1</sup> Details of the person discharging managerial responsibilities / person closely associated

a) Name Pascal Soriot

2 Reason for the notification

a) Position/status Chief Executive Officer

b) Initial notification /Amendment Initial notification

## Edgar Filing: ASTRAZENECA PLC - Form 6-K

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name AstraZeneca PLC
- b) LEI PY6ZZQWO2IZFZC3IOL08

- 4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Ordinary Shares of US\$0.25  
each in AstraZeneca PLC

- a) Description of the financial instrument, type of instrument

Identification code

GB0009895292

- b) Nature of the transaction

Acquisition of ordinary shares pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.

- c) Price(s) and volume(s)

|          |           |
|----------|-----------|
| Price(s) | Volume(s) |
| 0        | 115,793   |

Not applicable - single transaction

- d) Aggregated information
  - Aggregated volume
  - Price

- e) Date of the transaction

28 March 2017

- f) Place of the transaction

Outside a trading venue

- 1 Details of the person discharging managerial responsibilities / person closely associated

- a) Name Marc Dunoyer

- 2 Reason for the notification

- a) Position/status Chief Financial Officer

- b) Initial notification /Amendment Initial notification

- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name AstraZeneca PLC

- b) LEI PY6ZZQWO2IZFZC3IOL08

Edgar Filing: ASTRAZENECA PLC - Form 6-K

4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Ordinary Shares of US\$0.25  
each in AstraZeneca PLC

a) Description of the financial instrument, type of instrument

Identification code

GB0009895292

b) Nature of the transaction

Acquisition of ordinary shares pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.

c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|-----------|
| 0        | 26,897    |

Not applicable - single transaction

d) Aggregated information

- Aggregated volume  
- Price

e) Date of the transaction

28 March 2017

f) Place of the transaction

Outside a trading venue

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name

Mark Mallon

2 Reason for the notification

a) Position/status

Person Discharging  
Managerial Responsibilities

b) Initial notification /Amendment

Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

AstraZeneca PLC

b) LEI

PY6ZZQWO2IZFZC3IOL08

4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument

AstraZeneca PLC American  
Depositary Shares

Identification code

Edgar Filing: ASTRAZENECA PLC - Form 6-K

CUSIP: 046353108

Acquisition of ADSs pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.

| Price(s) | Volume(s) |
|----------|-----------|
| 0        | 22,620    |

b) Nature of the transaction

c) Price(s) and volume(s)

Aggregated information

d) - Aggregated volume  
- Price

Not applicable - single transaction

e) Date of the transaction

28 March 2017

f) Place of the transaction

Outside a trading venue

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 March 2017 By: /s/ Adrian Kemp

Name: Adrian Kemp

Title: Company Secretary